GB Sciences Inc GBLX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.01
- Day Range
- $0.01–0.01
- 52-Week Range
- $0.01–0.02
- Bid/Ask
- $0.01 / $0.01
- Market Cap
- $2.56 Mil
- Volume/Avg
- 6,845 / 131,567
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- 5.54%
Company Profile
GB Sciences Inc is active in the healthcare sector. The company is engaged in developing and utilizing technologies in plant biology, cultivation, and extraction techniques combined with biotechnology, and plans to produce medical-grade cannabis, cannabis concentrates, and cannabinoid therapies. It seeks to be a technology and solution company that converts the cannabis plant into medicines, therapies, and treatments for a range of ailments.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 3
- Website
- https://www.gbsciences.com
Valuation
|
Metric
|
GBLX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
GBLX
Financial Strength
|
Metric
|
GBLX
|
|---|---|
Quick Ratio | 0.00 |
Current Ratio | 0.03 |
Interest Coverage | −19.52 |
Quick Ratio
GBLX
Profitability
|
Metric
|
GBLX
|
|---|---|
Return on Assets (Normalized) | −149.71% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
GBLX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Bxdpnvgfh | Xrdtt | $553.3 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Hrtzyjnrj | Xqrwz | $101.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Bcqnkvp | Nscmyl | $98.9 Bil | |
MRNA
| Moderna Inc | Hgkxdcrc | Znhwx | $39.7 Bil | |
ARGX
| argenx SE ADR | Bwvqkdxm | Jbncr | $22.1 Bil | |
BNTX
| BioNTech SE ADR | Pqbmntr | Gmdm | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Gvngcvvm | Yrpzb | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Jzcxndyfh | Jdnshn | $17.2 Bil | |
RPRX
| Royalty Pharma PLC Class A | Xtqyhcwslq | Pzzsms | $12.3 Bil | |
INCY
| Incyte Corp | Dhhldfbv | Mrmgj | $11.8 Bil |